COMMUNIQUÉS West-GlobeNewswire

AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2026 et présente un point sur ses activités
09/10/2026
COMMUNIQU É DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2026 ET LES ÉVÉNEMENTS CLEFS DE LA PÉRIODE Évolution de la gouvernance d’AB Science et mise en place d’une nouvelle stratégie [...]
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
09/10/2026
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as [...]
Trillium Dental’s Dr. Mark Northcott Reveals Which Halloween Treats Damage Kids’ Teeth and Which Are Surprisingly Safe
09/10/2026
OTTAWA, Ontario, Oct. 09, 2026 (GLOBE NEWSWIRE) -- With Halloween approaching, Dr. Mark Northcott, co-founder of Trillium Dental and a Doctor of Dental Surgery from McGill University and Yale University, is advising [...]
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
09/10/2026
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO ® Agreement provides Profound with [...]
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
09/10/2026
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone ® [...]
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
09/10/2026
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Nextech Unveils Agentic AI Capabilities for Patient Experience through Partnerships with Assort Health and EliseAI
09/10/2026
Specialty practices gain a choice of two leading AI patient access platforms, unveiled at AAO 2026 in New Orleans TAMPA, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nextech , a leading technology partner for specialty [...]
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
09/10/2026
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited New analyses from the ARRECTOR and DERMIS-1/2 trials [...]
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
09/10/2026
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
09/10/2026
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph. [...]
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
09/10/2026
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of [...]
New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal Dementia
09/10/2026
Research presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis OXFORD, United Kingdom, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Oxford Brain Diagnostics [...]
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
09/10/2026
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, [...]
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
09/10/2026
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second- [...]
SkinHealth Systems Announces Reverse Stock Split
09/10/2026
Shares expected to begin trading on split-adjusted basis on October 14, 2026 LONG BEACH, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (Nasdaq: SKIN) (the “Company”), home to flagship brand Hydrafacial™, [...]
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
09/10/2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 [...]
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
09/10/2026
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study [...]
T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing
09/10/2026
Austin, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- T·Time Health Inc. , the telehealth brand at ttime.men, has launched cash-pay compounded injectable semaglutide and tirzepatide with one published rate regardless of [...]
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
09/10/2026
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with [...]

Pages